Fig. 4: cSNX1.3 peptide inhibits EGFR driven cancer cell viability.
From: Sorting nexin-dependent therapeutic targeting of oncogenic epidermal growth factor receptor
A–G Cells were plated in a 96-well plate at 2000 cells per well. The indicated concentration of cPTD4, cSNX1.3, Sapitinib, or Erlotinib were added to the cells on day 0 and incubated for 3 days. Cell viability was then measured with an MTT assay, viability of treated cells were compared with the vehicle control. H MDA-MB-468 cells were plated and incubated+/− IPTG for 2 days prior to drug treatment to induce expression of an EGFR-targeted shRNA. Cells were then additionally treated with cPTD4 or cSNX1.3 for 3 days, and then viability was measured using an MTT assay.
